News & Events

Sep
6

Bourne Partners Advises Accelovance on Sale of SMO, Optimal Research

September 6, 2017

ROCKVILLE, MD – In January 2017, Accelovance, Inc. (“Accelovance”), a global contract research organization (CRO) focused on oncology, vaccines and general medicine, engaged Bourne Partners (“Bourne”) to find an appropriate buyer for the company.

Upon initial review, Bourne Partners sought to run a typical CRO sell-side process and began the general course of action. After investigating the increased M&A activity around Site Management Organizations (SMOs), Bourne Partners and Accelovance changed the approach and chose to run a highly targeted process focusing solely on a handful of the largest CRO’s, all known by Bourne to be actively seeking SMO acquisition opportunities. It was clear that Accelovance would maximize its value by carving out its SMO, Optimal Research.

Optimal Research was sold to Synexus, part of PPD’s Accelerated Enrollment Solutions business unit, for an undisclosed amount in Q4 2017.

About Accelovance, Inc.
Accelovance is an award winning, clinical development CRO focused on oncology, vaccine, dermatology, pain, nutri­tion and women’s health (Phase I-IV programs). Providing global full CRO services to pharmaceutical companies, biotechs, CROs, and academic institutions, Accelovance supports client needs by leveraging operational knowl­edge and patient recruitment strategies that result in successful clinical trials. Established in 2005 with a corpo­rate mission to improve the quality and predictability in clinical research, Accelovance has made significant strides in the industry by combining strong business and opera­tional perspective with clinical and medical expertise. For more information, visit www.accelovance.com.

About Optimal Research
Optimal Research provides clinical site solutions to pharmaceutical and biotech companies, medical device companies, and contract research organizations (CROs) seeking research sites to conduct clinical research studies in a high quality manner. In addition to the six core sites that it owns, Optimal utilizes its oncology and pediatric site network to provide integrated site solutions that meet our client’s needs. Optimal is the intersection where pharma­ceutical/biotech companies and patients find excellence in clinical research. Specifically, Optimal provides clinical site infrastructure and staffing to meet the requirements of the clinical trial protocols for men’s and women’s health, geri­atrics, vaccine, oncology, and pediatric health conditions. For more information, visit www.optimalsites.net.